7 completed, 2 active not recruiting, 2 terminated, 2 unknown. 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 7, Active not recruiting 2, Terminated 2, Unknown 2, Withdrawn 1 |
Follow Neoplasms, Fibroepithelial: new trials by email Literature Review of Neoplasms, Fibroepithelial trials Research Report on Neoplasms, Fibroepithelial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Acetyl-L-Carnitine Hydrochloride, Placebo, Questionnaire Administration - Fatigue, Malignant Ovarian Mixed Epithelial Tumor | Phase 3 | Withdrawn | Gynecologic Oncology Group | 2012-04-01 | 2014-12-31 | |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer bevacizumab, carboplatin, paclitaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Completed | Medical Research Council | 1520 | 2006-04-01 | 2013-08-12 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | GOG Foundation | 1157 | 2005-03-21 | 2021-09-30 |
| MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas ExAblate 2000 - Breast Fibroadenoma | Phase 3 | Terminated | InSightec | 102 | 2003-01-01 | 2012-09-17 |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer carboplatin, paclitaxel - Ovarian Cancer | Phase 3 | Completed | Gynecologic Oncology Group | 571 | 1998-10-01 | 2019-06-04 |
| Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer cisplatin, paclitaxel, quality-of-life assessment - Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 3 | Completed | Gynecologic Oncology Group | 384 | 1998-03-01 | 2013-05-27 |
| Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer carboplatin, cyclophosphamide, mitoxantrone hydrochloride - Ovarian Cancer | Phase 3 | Terminated | Gynecologic Oncology Group | 1996-11-01 | 2013-04-11 | |
| Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer cisplatin, paclitaxel - Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 3 | Completed | Gynecologic Oncology Group | 324 | 1996-03-01 | 2013-05-27 |
| Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer cisplatin, paclitaxel, conventional surgery - Ovarian Cancer | Phase 3 | Completed | Gynecologic Oncology Group | 470 | 1994-06-01 | 2013-07-09 |
Brenner Tumor (13) · Ovarian Neoplasms (9) · Fallopian Tube Neoplasms (7) · Carcinoma, Ovarian Epithelial (6) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Breast Neoplasms (1) · Carcinoma (1) · Fatigue (1) · Fibroadenoma (1) · Neurotoxicity Syndromes (1) · Pain (1)
Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms, Connective Tissue (14) · Neoplasms, Connective and Soft Tissue (14) · Neoplasms, Fibrous Tissue (14) · Neoplasms, Glandular and Epithelial (14) · Adnexal Diseases (13) · Endocrine System Diseases (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Genital Diseases (13) · Genital Diseases, Female (13) · Genital Neoplasms, Female (13) · Gonadal Disorders (13)
Paclitaxel (11) · Carboplatin (7) · Bevacizumab (5) · Taxes (5) · Cisplatin (4) · Disulfides (4) · Immunoglobulin G (4) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Counseling (1) · Cyclophosphamide (1) · Docetaxel (1) · Early Intervention, Educational (1) · Educational Status (1) · Gemcitabine (1) · Methods (1)
Gynecologic Oncology Group (7) · National Cancer Institute (NCI) (4) · GOG Foundation (1) · InSightec (1) · Medical Research Council (1)
United States (12) · Japan (4) · Canada (3) · South Korea (3) · Australia (1) · France (1) · Germany (1) · Norway (1) · United Kingdom (1)
Clare Tempany, M.D. (1) · David Alberts (1) · David Kushner (1) · David R. Spriggs, MD (1) · David S. Alberts, MD (1) · Deborah K. Armstrong, MD (1) · Fred Steinberg, M.D. (1) · Hidemi Furusawa, M.D. (1) · Joan L Walker (1) · John K Chan (1) · Kenneth B. Miller, MD (1) · Larry J Copeland (1) · Mark DeLaurentis, M.D. (1) · Patrick J. Stiff, MD (1) · Peter G. Rose, MD (1)
PMID 37185961, PMID 21941283, PMID 30633128, PMID 16110020, PMID 16368440, PMID 16394300, PMID 16515585, PMID 17264340, PMID 17906207, PMID 18430468, PMID 18640939, PMID 19596139, PMID 21529904, PMID 22119995, PMID 22204724, PMID 22204725, PMID 23219660, PMID 26487588, PMID 26933849, PMID 27394382, PMID 28438473, PMID 29550184, PMID 31002578, PMID 31216226, PMID 31722153, PMID 35144591, PMID 35759733, PMID 36252167, PMID 36608382
U10CA027469 (5), U10CA180868 (5), U10CA101165 (2), U10CA180830 (1), UG1CA189867 (1)